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Am J Med Genet Part A 170A:2988–2992.The aim of this study was to identify the causative mutation in a
family with an unusual presentation of autosomal dominant
osteopetrosis (OPT), proximal renal tubular acidosis (RTA),
renal stones, epilepsy, and blindness, a combination of features
not previously reported.Weundertook exome sequencing of one
affected and one unaffected family member, followed by
targeted analysis of known candidate genes to identify the
causative mutation. This identified a missense mutation
(c.643G>A; p.Gly215Arg) in the gene encoding the
chloride/proton antiporter 7 (gene CLCN7, protein CLC-7),
which was confirmed by amplification refractory mutation
system (ARMS)-PCR, and to be present in the three available
patients. CLC-7 mutations are known to cause autosomal
dominant OPT type 2, also called Albers–Schonberg disease,
which is characterized by osteosclerosis, predominantly of the
spine, pelvis and skull base, resulting in bone fragility and
fractures. Albers–Schonberg disease is not reported to be asso-
ciated with RTA, but autosomal recessive OPT type 3 (OPTB3)
with RTA is associated with carbonic anhydrase type 2 (CA2)
mutations. No mutations were detected in CA2 or any other
genes known to cause proximal RTA. Neither CLCN7 nor CA2
mutations have previously been reported to be associated with
renal stones or epilepsy. Thus, we identified a CLCN7 mutation
in a family with autosomal dominant osteopetrosis, RTA, renal
stones, epilepsy, and blindness.2016TheAuthors.American Journal of
Medical Genetics Part A Published by Wiley Periodicals, Inc.
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DOI 10.1002/ajmg.a.37755INTRODUCTION
Osteopetrosis (OPT) comprises a heterogeneous group of diseases
characterized by high bone density with increased cortical and2016 The Authors. American Journal of Medical Genetics Parttrabecular bone thickness and susceptibility to fractures, that may
be due either to a reduction in the number of differentiated
osteoclasts, or to a defect in osteoclast function, resulting in
reduced bone resorption [Aggarwal, 2013]. The clinical severity
of these features is variable and OPT forms have traditionally been
distinguished by their age of onset, the affected bones, otherA Published by Wiley Periodicals, Inc. 2988
PIRET ET AL. 2989associated clinical features such as renal tubular acidosis,
neurological impairment, retinal atrophy, or immune defects
[Bollerslev et al., 2013; Sobacchi et al., 2013], and heritability,
with autosomal dominant OPT (ADO) having a later and less
severe onset than autosomal recessive OPT (ARO). However, there
are clinical overlaps between these forms of OPT, such that an
intermediate ARO (IARO) form has also been identified, and there
are also overlaps with other high bone density disorders whichmay
have similar radiological and clinical features [Warman et al., 2011;
Aggarwal, 2013], making it difficult to establish a diagnosis on the
basis of clinical features alone. For example, ADOType 1 (OPTA1),
due to mutations of low density lipoprotein receptor-related
protein 5 (LRP5), has been reclassified as a high bone mass disease
rather than classical OPT. Todate, defects in 25 different genes have
been demonstrated to cause OPT or other high bone density
disorders (Supplementary Table SI), and different mutations in
the chloride/proton antiporter 7 (gene symbolCLCN7, and protein
symbol CLC-7) have been reported to cause ADO, ARO, or IARO
[Bollerslev et al., 2013; Sobacchi et al., 2013]. Moreover, mutations
of CLC-7, which provides a Cl countercurrent to allow acidifica-
tion of the osteoclast resorption lacuna [Bollerslev et al., 2013],
cause ADO type 2 (OPTA2), also called Albers–Schonberg disease,
which is characterized by osteosclerosis predominantly affecting
the spine, pelvis and skull base and resulting in bone fragility,
fractures, and dental abscesses [Bollerslev et al., 2013].
Here, we report a family with ADO with variable expressivity,
associated with renal tubular acidosis (RTA), renal stones, develop-
mental delay, blindness and epilepsy (Fig. 1A), a combination of
features not previously reported.RTA is not a feature ofOPTA2, but
is only associatedwithAROtype 3 (OPTB3), due tomutationsof the
geneencodingcarbonicanhydrase type II (gene symbolCA2, protein
symbol CAII) [Sobacchi et al., 2013]. RTA, which may be of
proximal (pRTA) or distal (dRTA) tubular origin, occurring with-
out OPT may be associated with mutations in >10 genes (Supple-
mentary Table SII). Thus, >35 genes may be associated with OPT
(Supplementary Table SI) and pRTA (Supplementary Table SII),
and to determine the causative mutation in this unusual family, we
undertook exome sequencing and cosegregation analysis.MATERIALS AND METHODS
Patients and Clinical Findings
Informed consent and venous blood samples were obtained from
the four available individuals (three affected, one unaffected) of
the family with ADO (Fig. 1A), using protocols approved by the
Multicentre Research Ethics Committee (UK) (MREC/02/2/93),
and local and national ethics committees (Australia). The pro-
band (Fig. 1A, individual III.11), a 49-year-old woman, had
presented at the age of 2 years with a fractured tibia caused
by falling out of bed. She had fractures of the opposite tibia aged
3 years, and ankle, aged 13 years, that required open reduction,
and internal fixation. Radiographs revealed increased bone den-
sity, consistent with OPT. She continued to have fractures of her
humeri, femur, tibiae, fingers and toes, such that she became
wheelchair bound by 35 years of age. At age 36 years, a dual-
energy X-ray absorptiometry (DXA) scan revealed a Z-score ofþ5.6 at the lumbar spine and þ3.5 at the proximal hip, and
concurrent X-rays demonstrated increased bone density with a
“bone within bone” appearance of the sacral ala and both femoral
heads (Fig. 1B), a typical feature of OPT. MRI has demonstrated a
rugger-jersey spine (Fig. 1C), which is associated with OPTA2,
although she does not have osteosclerosis of the skull. Serum
concentrations of C-telopeptide (CTX) of 85 ng/L (reference
range 100–700 ng/L) and N-terminal propeptide of type one
collagen (P1NP) of 9mg/L (reference range< 59mg/L) are con-
sistent with a low bone turnover state, but serum lactate dehy-
drogenase (LDH) isoenzymes were elevated at 533 U/L (reference
range 210–420U/L), consistent with OPTA2 [Whyte et al., 2010].
In her 4th decade, she had severe asthma episodes that required
high-dose glucocorticoids, and despite chronic carbon dioxide
retention and a respiratory acidosis, her plasma bicarbonate
levels were inappropriately normal and associated with
significant hypokalemia, consistent with a pRTA. However,
she did not have phosphaturia, uricosuria, glycosuria or amino-
aciduria, thereby excluding a renal Fanconi syndrome, and she
was able to acidify her urine when challenged with an ammonium
chloride loading test from pH> 5.5 to pH< 5.3, thereby exclud-
ing a dRTA (Supplementary Table SIII). In addition, her plasma
bicarbonate remained at the lower end of the normal range
(22.1–24.6mmol/L), despite oral bicarbonate treatment, whilst
her urinary pH rose to 6.55–6.92, consistent with a defect in renal
bicarbonate reabsorption, and a pRTA. However, she did not
have intracerebral calcifications, cognitive impairment, and hear-
ing loss, which occur in patients with OPTB3, who have autoso-
mal recessive OPT with pRTA. Moreover, OPT in the proband’s
family was inherited as an autosomal dominant trait (Fig. 1A) in
association with pRTA, blindness, epilepsy and renal stones, a
combination that has not previously been reported.Exome Sequencing and Variant Confirmation
LeukocyteDNAwas extracted and used for exome capture, utilizing
DNAfromoneaffectedandoneunaffected individual.Variantswere
confirmed by DNA Sanger sequence analysis, and amplification-
refractory mutation system (ARMS)-PCR (Supplementary
Methods).RESULTS
Exome sequencing identified a single nucleotide variant,
c.643G>A, in CLCN7, encoding a missense substitution,
Gly215Arg, which has been reported to be a mutation causing
OPT in multiple families with OPT2A [Cleiren et al., 2001;
Bollerslev et al., 2013]. This variant, located in exon seven of
CLCN7, was confirmed by DNA Sanger sequence analysis (data
not shown) in the proband and by ARMS-PCR to occur as a
heterozygous variant in the three affected individuals and to be
absent in the unaffected relative and 100 control unaffected, and
unrelated individuals of European origin (Fig. 1D, E). This
CLCN7 variant was also absent from >57,000 exomes from
the Exome Aggregation Consortium (ExAC) database. Thus,
these data demonstrate that this Gly215Arg CLC-7 mutation is
the cause for this autosomal dominant form of OPT. Samples
FIG. 1. A: Pedigree of proband (arrowed) with OPT and pRTA. Inheritance of OPT by a son (individual IV.4), with developmental delay (DD),
from his father (III.8) demonstrates male-to-male transmission, a hallmark of an autosomal dominant disorder. Individual III.6, at age
24 years had back pain, and X-rays revealed dense bones, consistent with OPT; he has not had any fractures but has multiple renal
stones (RS) containing calcium. His daughter (IV.2) had fractured toes and radiographs revealed dense bones, consistent with OPT. A
maternal cousin (III.17) had multiple humeral and femoral fractures, and was diagnosed with OPT aged 38 years; she has epilepsy (Ep)
with seizures occurring 8–10 times per day despite medical therapy. Her son (IV.11), born blind (Bl), also has epilepsy, is now aged
35 years, and has suffered from multiple fractures due to OPT. The mother (II.4) and father (II.3) of the proband have not developed any
clinical or radiological signs of OPT. None of the relatives of the proband with OPT and pRTA, has hyperchloremic metabolic acidosis. Prem:
premature birth. B: Pelvic radiograph of proband, showing “bone within bone” appearance of sacral ala and femoral heads (arrowheads). C:
Lateral MRI scan of proband, showing a rugger-jersey spine. D: CLCN7 c.643G>A mutation, confirmed by ARMS-PCR in the proband, and
shown to be present in affected relatives, and absent in an unaffected relative, and in 100 unrelated unaffected individuals, of whom 2
(N1 and N2) are shown. ARMS-PCR products (wild-type [W] and mutant [m]) are shown below each individual; with “g” and “a” denoting
genomic and ARMS bands, respectively. pRTA is likely due to the CLCN7 mutation, rather than a second mutation in a gene known to
cause pRTA, as 88% of the coding regions of genes were covered by exome sequencing at a read depth that would allow detection of
such variants. E: Location of primers in relation to exon 7 and the mutated nucleotide (bold).
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gation analysis, and variants of CA2 or other candidate genes for
pRTA (Supplementary Table SII) were not identified.DISCUSSION
Our study reports a family with ADO in association with pRTA,
renal stones, epilepsy, and blindness. Such a combination of clinical
featureshasnotbeenpreviously reported. TheOPTwas identified tobe due to a CLC-7 mutation, Gly215Arg, and thus, this family has
Albers–Schonberg disease, which is characterized by diffuse,
symmetrical osteosclerosis mainly affecting the spine, pelvis and
skull, increased fracture rate, and severe vision loss beginning in
childhood in20% of patients [Waguespack et al., 2007; Bollerslev
et al., 2013]. Moreover, 20–40% of CLC-7 mutation carriers
remain asymptomatic, consistent with variable expressivity
[Waguespack et al., 2007; Bollerslev et al., 2013]. Thus, these features
of Albers–Schonberg disease are consistent with those observed in
this family (Fig. 1A), in which there are 12 individuals affected with
PIRET ET AL. 2991ADO, with one having blindness, and there are three asymptomatic
obligate heterozygotes, indicating variable expressivity. However,
CLC-7 mutations have not previously been reported in association
with renal abnormalities, such as pRTA and renal stones, or with
epilepsy, thereby indicating that Albers–Schonberg disease may be
associated with additional clinical features.
CLC-7 is a chloride/proton antiporter that is ubiquitously
expressed, and found predominantly on the membranes of endoly-
sosomal vesicles [Lange et al., 2006]. In osteoclasts, CLC-7 is also
found in the ruffled membrane, where with its b-subunit, the
OPT-associated transmembrane protein 1 (OSTM1), mutations of
which result in ARO type 5 (OPTB5) (Supplementary Table SI), it
functions to provide a Cl countercurrent for acidifying the resorp-
tion lacuna [Lange et al., 2006]. The CLC-7 Gly215Arg mutation
reducesosteoclast activityby80–90%[Henriksenetal., 2004;Schulz
et al., 2010], andClcn7 null (Clcn7/) mice develop severe OPT and
retinal degeneration [Kornaket al., 2001],but arenot reported tohave
RTA. However, renal proximal tubules (PT) from mice with
PT-specific deletion of Clcn7 had enlarged endolysosomal vesicles
in which degradation of endocytosed protein was impaired, suggest-
ing an important role for CLC-7 in the renal PT [Wartosch et al.,
2009]. Moreover, rare variants, deletions, duplications or copy num-
ber variations were not detected in other pRTA causing genes in the
family with OPT and pRTA, thereby indicating that pRTA may be a
new clinical feature associated with CLC-7 mutations, and studies of
additional OPT patients harboring CLC-7 mutations may help to
further elucidate this.
The variable clinical features of OPT in the family (e.g., epilepsy
in individuals III.17 and IV.11 [Fig. 1A]), is consistent with
previous observations in families with ADO [Bollerslev et al.,
2013], and may be due to digenic inheritance (co-inheritance of
two rare recessive disorders), or geneticmodifiers. For example, the
occurrence ofOPT anddRTA in a Turkish kindred is due to digenic
inheritance comprising: a homozygous deletion ofTCIRG1, result-
ing in ARO type 1 (OPTB1) (Supplementary Table SI); and a
homozygous mutation of the ATPase, proton (Hþ) transporting
lysosomal 50/58 kDaVI subunit B1 (ATP6V1B1) resulting in dRTA
[Borthwick et al., 2003]. Samples from individuals III.17 and IV.11
(Fig. 1A) with OPT and epilepsy were not available to investigate
for such digenic inheritance of epilepsy andOPT, which was due to
the CLCN7 mutation. Genetic modifiers may also contribute to
variable expressivity of OPT, as illustrated by breeding of a knock-
in mouse model with a CLC-7 Gly213Arg mutation, the equivalent
of the human CLC-7 Gly215Arg mutation, onto five different
genetic backgrounds, which revealed differences in the severity
of bone disease, such as the bone volume/total volume, which was
increased bytwo fold but only1.4 fold in heterozygous mutant
mice on 129 and D2 backgrounds, respectively, when compared to
wild-type mice [Alam et al., 2014].
Thus, our identification of a CLC-7 mutation in a family with
OPT and multiple clinical features, reveals a potential role for
CLC-7 in renal proximal tubular physiology.ACKNOWLEDGMENTS
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